Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

Weidmann, E; Neumann, A; Fauth, F; Atmaca, A; Al-Batran, S E; Pauligk, C; Jäger, E

Weidmann, E; Neumann, A; Fauth, F; Atmaca, A; Al-Batran, S E; Pauligk, C; Jäger, E.

Affiliation

Weidmann E; Department of Oncology and Hematology, Hospital Nordwest, Frankfurt am Main, Germany. weidmann.eckhart@khnw.de

Ann Oncol ; 22(8): 1839-44, 2011 Aug.

Article in En | MEDLINE | ID: mdl-21257672

Subject(s)

Antibodies, Monoclonal, Murine-Derived/administration & dosage; Antineoplastic Combined Chemotherapy Protocols; Lymphoma, B-Cell/drug therapy; Nitrogen Mustard Compounds/administration & dosage; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived/adverse effects; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell/pathology; Male; Neoplasm Staging; Neutropenia/etiology; Nitrogen Mustard Compounds/adverse effects; Rituximab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, B-Cell / Antibodies, Monoclonal, Murine-Derived / Nitrogen Mustard Compounds Type of study: Etiology_studies / Prognostic_studies Limits: Aged80 / Female / Humans / Male Language: En Journal: Ann Oncol Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google